Core Framework & DiagramWhat Is Immune Microenvironment Engineering?

Modified oncolytic viruses (like T-VEC) are engineered to only effectively replicate in cancer cells (exploiting cancer cells' antiviral defects); in normal cells, intact antiviral mechanisms prevent viral replication. Despite this, close monitoring after local injection is still needed, including herpes virus-related skin symptoms and immune-related adverse reactions. Overall, the safety record of approved oncolytic virus products is acceptable.

Systemically activating STING produces a strong systemic type I interferon response, causing severe cytokine storm-like toxic side effects — high fever, hypotension, multi-organ inflammation. This caused unacceptable toxicity in early systemic administration trials. Intratumoral injection confines STING activation to the local tumor, avoiding systemic toxicity — the mainstream clinical development route for STING agonists currently.

This is exactly a highly promising combination direction. NK cell therapy (CAR-NK or expanded NK cell reinfusion) brings high-activity killing cells to the tumor; immune microenvironment engineering (STING agonists, CAF targeting, vessel normalization) improves conditions for NK cells to enter tumors and work. The two are theoretically highly complementary — one provides 'better soldiers,' the other provides 'better battlefield.' Clinical preclinical studies for this type of combination are advancing rapidly.

Yes, especially in chronic infections (like tuberculosis, HIV latent virus activation control) and autoimmune diseases (using similar logic to 'cool down' overactivated autoimmune microenvironments). For example, in RA joint synovium, targeting the fibroblast subsets driving inflammation is currently one of the most promising new treatment targets — an application of the same microenvironment engineering thinking to autoimmune disease.